Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00804505 · ClinicalTrials.gov registry record · NA
Hybrid SA RGP Center/S-H Skirt Daily Wear 90 Day Multicenter Study
A NA study of Hypersensitivity and Corneal Disease, sponsored by SynergEyes.
- Completed
- Registry status
- NA
- Development phase
- 98
- Enrollment target
- 8
- Study locations
NCT00804505: Completed NA study of Hypersensitivity and Corneal Disease, sponsored by SynergEyes.
NCT00804505 is a NA study of Hypersensitivity and Corneal Disease that has completed, run by SynergEyes. The registered enrollment target is 98 participants, below the 172-participant average among 8 other Hypersensitivity trials with a reported enrollment target (43% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00804505, a NA study of Hypersensitivity and Corneal Disease, has completed, sponsored by SynergEyes.
- COMPLETED
- Registry status
- NA
- Development phase
- 98 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of the study is to demonstrate that the SynergEyes SA Hybrid Contact Lens clinical performance is substantially equivalent to that of the SynergEyes A Hybrid Lens when studied: * within the corresponding range of lens powers * in a population randomized within multiple investigational sites * with a study ration of 2/1 test vs control lenses * for a duration of 90 days.
Conditions Studied
Interventions
- DEVICE SynergEyes Hybrid (petrafocon A hem-larafilcon A) Hybrid Contact Lens
- DEVICE SynergEyes Hybrid (paflufocon D hem-iberfilcon A) Contact Lens
Study Locations (8)
California
- Carmel Mountain Vision Care - San Diego
- Silicon Valley Eye Physicians - Sunnyvale
Massachusetts
- Casazza Optometric Group - Andover
Michigan
- Vision Care Associates - East Lansing
Ohio
- Western Reserve Vision Care, Inc. - Beachwood
Rhode Island
- Dr. Karambelas & Associates - Providence
Tennessee
- Primary Eyecare Group P.C. - Brentwood
Wyoming
- Snowy Range Vision Center - Laramie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2008-06 |
| Est. Completion | 2008-12 |
| Phase | NA |
What the finished NCT00804505 record still lists
NCT00804505 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 98 participants, a relatively small participant target, below the 172-participant average among 8 other Hypersensitivity trials with a reported enrollment target (43% lower).
The record links to 2 conditions, with Hypersensitivity appearing as the primary indexed condition, and to 2 interventions - of which SynergEyes Hybrid (petrafocon A hem-larafilcon A) Hybrid Contact Lens is the first listed.
NCT00804505 lists 8 locations in 7 states (California, Massachusetts, Michigan).
Frequently Asked Questions
What is clinical trial NCT00804505 about?
NCT00804505 is a clinical study titled "Hybrid SA RGP Center/S-H Skirt Daily Wear 90 Day Multicenter Study". The purpose of the study is to demonstrate that the SynergEyes SA Hybrid Contact Lens clinical performance is substantially equivalent to that of the SynergEyes A Hybrid Lens when studied: * within the corresponding range of lens powers * in a population randomized within multiple investigational s...
What is the current status of trial NCT00804505?
This trial is currently completed. It is a NA study. The enrollment target is 98 participants. The study started on 2008-06. Estimated completion is 2008-12.
What conditions does trial NCT00804505 study?
This clinical trial studies the following conditions: Hypersensitivity, Corneal Disease.
What interventions are being tested in trial NCT00804505?
The interventions under investigation include: SynergEyes Hybrid (petrafocon A hem-larafilcon A) Hybrid Contact Lens (DEVICE), SynergEyes Hybrid (paflufocon D hem-iberfilcon A) Contact Lens (DEVICE).
Who is sponsoring clinical trial NCT00804505?
This trial is sponsored by SynergEyes, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00804505 being conducted?
This trial has 8 study locations across California, Massachusetts, Michigan, Ohio, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypersensitivity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00804505's enrollment target sits among peer trials
98 4th of 8 higher than 5 of 8 other Hypersensitivity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypersensitivity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pilot Study to Investigate the Efficacy of a Toothpaste in Providing Relief From Dentinal Hypersensitivity
COMPLETED · NA
-
Asthma Data Innovation Demonstration Project
COMPLETED · NA
-
Activation and Function of Eosinophils in Conditions With Blood or Tissue Eosinophilia
RECRUITING
-
Omalizumab (Xolair) and Allergy Shots For the Treatment of Seasonal Allergies
COMPLETED · Phase 2
-
Oral Bacteria and Allergic Disease in Children
COMPLETED
-
Phase II Efficacy Study of Aerosolized Recombinant Human IL-4 Receptor in Asthma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02926729 · 98 participants · NA
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia